How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer’s disease? And what on Earth is an “oversubscribed Series A round”?
We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation with Dr. Peter Bach of Memorial Sloan Kettering Cancer Center about just how the government should pay for those pricey-but-effective new CAR-T therapies. Then we break down some of the jargon startups employ when they raise money and explain why some of it doesn’t exactly mean what you might think. Also STAT’s Sharon Begley joins us to talk about why the drug industry’s Alzheimer’s pipeline offers so little hope to patients already showing symptoms of the disease, and we embark on a lightning round touching on Gilead Sciences’ changing of the guard, gene therapy’s commercial future, and why good news at the FDA can be bad news on Wall Street.